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Abstract
Introduction: The authors aimed to compare the distribution of COPD based on the new GOLD grading with stadium based 
exclusively on spirometry. 
Material and methods: Eligible patients had an average age of 64.8 years and smoked at least 10 pack-years. COPD was defined 
according to GOLD fixed cut-off criterion FEV1/FVC < 0.70. In all patients postbronchodilator spirometry was performed. Cate-
gories were defined with the mMRC dyspnoea scale and CAT scale. COPD exacerbations in the previous year and lung function 
were evaluated. Statistical comparisons were done using t-student test.
Results: 315 COPD patients, 99 (31.4%) women and 216 (68.6%) men, were examined. Mean pack-years in the whole group was 
47.1 ± 17.8. In women this figure was less than in men, 43.7 ± 19.2 vs 49.5 ± 16.5 (p > 0.05), respectively. At study entry, 
144 subjects (45.7%) were current smokers, and the majority of them (n-87, 60.4%) belonged to category D — 26/66 (54.5%) 
women and 51/102 (50%) men. Based on spirometry alone, the patients were classified as moderate COPD 144 (45.71%), severe 
– 154 (48.89%), and very severe 17 (5.4%). According to the 2011 GOLD report stratification, 60 patients (19.04%) were graded 
as category A, 63 (20%) as category B, 24 (7.62%) as category C, and 168 (53.33%) as category D, although 21 (12.5% of them) 
were in category B, but the number of exacerbations classified them as category D.
Conclusions: The COPD population is heterogeneous in reference to the symptoms, value of FEV1, and susceptibility to exacerbations. 
Clinical symptoms assessed using validated questionnaires characterized COPD patients better than the value of spirometric parameters 
(which are necessary for diagnosis of this disease). Some patients were difficult to classify, especially those belonging to category C.
Key words: category ABCD, CAT questionnaire, COPD, 2011 GOLD report, spirometry
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Streszczenie
Wstęp: Celem pracy było porównanie rozkładu POChP według nowej gradacji GOLD ze stadium ocenianym wyłącznie na pod-
stawie spirometrii.
Pacjenci i metody: Pacjenci spełniający warunki byli w wieku 64,8 roku i palili papierosy co najmniej 10 paczkolat. POChP było 
zdefiniowane według GOLD z wartością FEV1/FVC < 0,70 po teście odwracalności obturacji. Kategorie zostały określone według 
skali duszności mMRC i skali CAT. Oceniano zaostrzenia POChP w ciągu ostatniego roku i wskaźniki wentylacji. Opracowanie 
statystyczne wykonano przy użyciu testu t-studenta.
Wyniki: W badaniach analizowano 315 pacjentów z POChP: 99 (31,4%) kobiet i 216 (68,6%) mężczyzn. Palenie papierosów okre-
ślone średnią wartością paczkolat w całej grupie wynosiło 47,1 ± 17,8, ale średnia paczkolat u kobiet była krótsza niż u mężczyzn, 
odpowiednio 43,7 ± 19,2 vs 49,5 ± 16,5 (p > 0,05). Przy przystępowaniu do badania 144 osoby (45,7%) nadal paliły papierosy, 
większość z nich (n-87 — 60,4%) należała do kategorii D — 36/66 (54,5%) kobiet i 51/102 (50%) mężczyzn. Na podstawie tylko 
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spirometrii POChP umiarkowaną sklasyfikowano u 144 pacjentów (45,71%), ciężką u 154 (48,89%), a bardzo ciężka u 17 (5,4%). 
Według raportu GOLD 2011 60 pacjentów (19,04%) zostało zakwalifikowanych do kategorii A, 63 (20%) do kategorii B, 24 (7,62%) 
do kategorii C i 168 (53,33%) do kategorii D, chociaż 21 (12,5%) z nich było w kategorii B, lecz liczba zaostrzeń spowodowała 
zakwalifikowanie ich do kategorii D. 
Wnioski: Populacja z POChP jest heterogenna pod względem objawów, wartości FEV1 i podatności na zaostrzenia. Objawy klinicz-
ne oceniane przy użyciu zwalidowanych kwestionariuszy lepiej charakteryzują pacjentów z POChP niż wskaźniki spirometryczne, 
które są konieczne w diagnozowaniu tej choroby. Niektórych pacjentów trudno sklasyfikować, szczególnie tych do kategorii C. 
Słowa kluczowe: kategorie A, B, C, D, kwestionariusz CAT, POChP, raport GOLD 2011, spirometria
Pneumonol. Alergol. Pol. 2014; 82: 415–421
Introduction
Chronic obstructive pulmonary disease 
(COPD) is one of the leading causes of morbidi-
ty and mortality worldwide, and it is expected 
to increase over the coming decades. In 1990 
COPD was the sixth cause of death, and in 2030 
it is estimated that it will become the fourth le-
ading cause of death worldwide [1]. The cardinal 
symptoms of COPD are chronic and progressive 
dyspnoea, chronic cough, and sputum production 
in patients with a history of current or former ci-
garette smoking or exposure to other risk factors 
such as passive smoking and occupational agents 
[2]. In COPD-suspected patients, spirometry is 
required because this disease is characterised by 
persistent airflow limitation, which is confirmed 
by post-bronchodilator FEV1/FVC < 0.70 [2].
Morbidity from COPD may be affected by 
other comorbid chronic conditions, including car-
diovascular disease, skeletal muscle dysfunction, 
metabolic syndrome, osteoporosis, depression, 
or lung cancer [3–5]. The comorbidities occur in 
patients with different stages of airflow limitation. 
Worsening airflow limitation is associated with 
the increasing prevalence of exacerbation and 
the risk of death [6]. A great number of clinical 
trials proved that the severity of airflow limi-
tation described according to previous GOLD 
reports alone have not characterised COPD in 
individual patients because the level of FEV1 is 
an inadequate descriptor of the impact of COPD 
on a patient [6–8]. 
The 2011 GOLD consensus proposed a new 
approach to patients with COPD as well as COPD 
assessment, which enables the understanding of 
the impact of COPD on an individual patient [9]. 
The goal of combined personalised COPD assess-
ments is to determine the severity of the disease, 
including the severity of airflow limitation, and 
to assess the symptoms of COPD using validated 
questionnaires that evaluate the degree of disabi-
lity due to breathlessness and the impact of the 
disease on a patient’s daily life and well-being. 
Recently, several multidimensional indices have 
been presented for prognostic purposes in COPD 
[10–12].
The aim of the study was to determine the 
distribution of the new groups as proposed by 
2011 GOLD report category A, B, C, and D by 
using combined personalised COPD assessment 
and to compare it to previous categorisation of 
the same patients.
Material and methods
The study was performed on patients suf-
fering from COPD, diagnosed at least two years 
before in an outpatient pulmonary clinic. The 
patients were enrolled from 1 February, 2011 to 
8 April, 2012. COPD was defined by history of 
smoking more than 10 pack-years (defined as 
20 cigarettes a day for 10 years or 10 cigarettes 
a day for 20 years), FEV1 (expiratory volume in 
one second) less than 80% of the predicted value, 
and post-bronchodilator FEV1/FVC (after broncho-
dilator use) less than 0.70. The patients’ COPD 
before their enrolment to the study was clinically 
stable for at least six weeks before entry and they 
received optimal medical therapy according to 
the previous GOLD report [2]. All the participants 
gave their informed, written consent to participate 
in it and the study was approved by the Bioethics 
Committee of the Medical University of Łódź, 
Poland. All exams of individual patients were 
carried out on the same day.
In all patients, spirometry tests were perfor-
med at baseline and 15 minutes after the admi-
nistration of 400 mcg of salbutamol in accordan-
ce with the American Thoracic Society (ATS)/
European Respiratory Society (ERS) consensus 
criteria of acceptability and reproducibility, using 
a volumetric storage spirometer (Vitalograph 
2160, Vitalograph Ltd.) [13]. Airway limitation 
was stratified using ATS/ERS and GOLD report 
severity classification as follows: mild (FEV1% 
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≥ 80), moderate (FEV1% 50–79), severe (FEV1% 
30–49), and very severe (FEV1% < 30) [2, 9, 14]. 
Assessment of symptoms in our COPD pa-
tients was done using two validated question-
naires recommended by the 2011 GOLD report. 
Functional dyspnoea was evaluated by Modified 
British Medical Research Council (mMRC) dysp-
noea index, which assesses only breathlessness 
(scale 0–4) [15]. The other was the COPD Assess-
ment Test (CAT) (scale 0–40), which describes the 
patient’s daily life and the impact of COPD on his/
her well-being. This questionnaire is more repe-
atable and less sensitive to change than mMRC 
[16]. A CAT score ≥ 10 and mMRC ≥ 2 indicates 
a high level of symptoms [17, 18].
The annual exacerbation was calculated on 
the basis of an individual patient’s history and me-
dical documentation from the previous 12 months. 
An exacerbation of COPD was characterised by 
the definition given by Burge and Wędzicha [19]. 
According to this definition, COPD exacerbation 
is an acute event characterised by a worsening of 
the patient’s respiratory symptoms that is beyond 
normal day-to-day variations and leads to the need 
for a change in medication. Only these exacerba-
tions of COPD, which required hospitalisation or 
treatment with antibiotics and/or systemic corti-
costeroids, were taken into account. Patients with 
two or more exacerbations during the last year 
were considered to have frequent exacerbations.
In the study, 2011 GOLD report grading of the 
stage of COPD severity was used [9]. According 
to this new approach, four categories of COPD 
are proposed. 
Category A: low risk, mild or moderate airway 
limitation GOLD1, GOLD2, fewer symptoms 
mMRC < 2, CAT score < 10 and/or ≤ 1 exa-
cerbation per year. Category B: low risk, more 
symptoms, GOLD1 or GOLD2 (mild and moderate 
airflow limitation), mMRC ≥ 2, CAT score ≥ 10, 
≤ 1 exacerbation per year. Category C: high risk, 
fewer symptoms, GOLD3 or GOLD4 (severe or 
very severe airflow limitation, mMRC < 2, CAT 
score < 10, ≥ 2 exacerbations per year. Category D: 
high risk, more symptoms, GOLD3 or GOLD4, 
mMRC ≥2, CAT score ≥ 10, ≥ 2 exacerbation per 
year. Assessment of exacerbation risk was calcu-
lated for individual patients. 
Statistical analysis
Descriptive data are reported as mean ± SD or 
percentage, as appropriate. Comparisons between 
groups were performed using t-student test. In 
all analysis, a value < 0.05 was considered for 
statistical significance. 
Results
The study included 99 (31.4%) women and 
216 (68.6%) men with mean age of 64.8 ± 7.0 
years. The women were younger than the men 
(63.2 ± 7.6 vs. 66.5 ± 6.4, p > 0.05). Mean time 
of COPD duration in the whole group was 6.3 
± 3.7 years (range: 2–20 years) (Table 1). Mean 
pack-years in the whole group was 47.1 ± 17.8. 
The number of mean pack-years in women was 
less, at 43.7 ± 19.2 (range: 20–120), than in men 
– 49.5 ± 16.5 (range: 25–90 but not significantly 
p > 0.05) (Table 1). 
At study entry 144 (45.7%) subjects were 
current smokers, and the majority of them (n-87; 
60.4%) were category D 36/66 (54.5%) women and 
51/102 (50.0%) men, current cigarettes smokers 
(that probably explains why the smokers were 
in category D); other patients gave up smoking 
mainly after experiencing a cardiovascular event. 
Based on spirometry alone, the patients from 
the group which we examined were classified 
based on FEV1 as moderate — 144 (45.71%), 
severe — 154 (48.89%), and very severe — 17 
(5.4%) (Table 2). According to the 2011 GOLD 
report stratification, 60 patients (19.04%) were 
graded as category A (low risk, less symptoms), 
Table 1.  Patient demographics and baseline characteristics
Number of patients 315
Age at enrolment (yrs)
(range)
64.8 ± 7.0
(50–81)
The time of COPD duration (yrs)
(range)
6.3 ± 3.7
(2–20)
Pack years smoked
(range)
47.1 ± 17.8
(20–120)
Current smokers
n (%)
144 (45.7%)
Female gender
n (%)
age
mean-pack-years
(range)
99 (31.4%)
63.2 ± 7.6*
 43.7 ± 19.2**
(20.0–120)
Male gender
n (%)
age
mean-pack-years
(range)
216 (68.6%)
 66.5 ± 6.4*
 49.5 ± 16.5**
(25.0–90.0)
Post bronchodilator FEV1 % pred.
< 30, n (%)
≥ 30 < 50, n (%)
≥ 50, n (%)
17 (5.4)
154 (48.89)
144 (45.71)
Data are presented as mean ± SD; *p > 0.05; **p > 0.05
Pneumonologia i Alergologia Polska 2014, tom 82, nr 5, strony 415–421 
418 www.pneumonologia.viamedica.pl
63 (20.0%) as category B (low risk, more symp-
toms), 24 (7.62%) as category C (high risk, less 
symptoms), and 168 (53.33%) as category D (high 
risk, more symptoms) (Table 3). Among them, 21 
(12.5%) subjects were classified as II old group; 
however, analysis of their mMRC and CAT scores 
classified them as category B, but the number of 
COPD exacerbations meant that they were stra-
tified in category D.
According to the 2011 GOLD report, ‘if there 
is a discrepancy between the risk category as 
assessed by spirometric classification and that 
derived from exacerbation history, the assessment 
pointing to the highest risk should be used.’ That 
explains why some patients with moderate COPD 
were stratified to category D.
Discussion
According to the 2001 GOLD consensus 
report and its update in 2006, the diagnosis, as-
sessment of severity, and treatment of COPD were 
guided by the degree of airflow limitation that 
was not fully reversible. Thus, the GOLD reports 
recommended the staging of COPD severity on 
the basis of spirometry alone [2]. But some cli-
nical trials established that COPD is a complex, 
heterogeneous disease with numerous pulmonary 
and extrapulmonary components [20, 21]. Finally, 
the ECLIPSE cohort proved that COPD is charac-
terised by heterogeneity with respect to clinical 
presentation, physiology, imaging, response to 
therapy, decline in lung function, and survival 
[6]. FEV1 by itself failed to adequately describe the 
complexity of this disease. Recently, Casanova et 
al. [22] in a longitudinal study of a COPD cohort 
showed that the progression of COPD is highly 
heterogeneous, because most observed patients 
(73%) had no decline in FEV1 characteristics for 
COPD. Based on clinical and functional variables, 
several validated, multidimensional indices have 
been offered for clinical practices. Among them is 
the BODE index (Body Mass Index, FEV1, Dysp-
noea, and Exercise capacity) which has proven 
Table 2. Stratification of COPD patients based on the old groups and categories ABCD (GOLD 2011)
Old GOLD
 group
Categories Total N (%)
A B C D
II 60 63 – 21 144 (45.71)
III – – 23 131 154 (48.89)
IV – – 1 16 17 (5.4)
Total N (%) 60 (19.04) 63 (20.0) 24 (7.62) 168 (53.3) 315 (100)
Table 3. Categories ABCD according 2011 GOLD Report
A B C D
Number of patients (%) 60 (19.05) 63 (20) 24 (7.62) 168 (53.33) 315 (100)
Sex F/M 9/51 24/39 0/24 66/102 99/216
Age (yers)
(range)
64.8 ± 6.5
(50–75)
65.5 ± 6.6
(51–78)
67.5 ± 5.8
(59–77)
64.6 ± 7.5
(51–81)
NS
Duration of COPD in years
(mean ± SD)
Female 5.6 4.5 – 7.4
Male 5.8 8.6 4.8 6.5
Pack-years
(range)
Female 39.4 ± 7.8*
(27–46)
38.6 ± 5.0**
(31–45)
– 46.5 ± 22.9***
(20–120)
NS
Pack-years
(range)
Male 45.7 ± 19.2*
(26–90)
45.1 ± 13.6**
(25–70)
49.1 ± 7.7
(45–74)
55.5 ± 17.3***
(25–90)
NS
FEV1 mean % pred value
(range)
64.0
(52.4–72)
58.54
(53–72)
47.56
(27–48.1)
45.8
(27.6–64)
CAT scores
(range)
8.14
(7 –9)
14.7
(10–22)
9.8
(8–9)
22.35
(13–25)
Data are presented as mean ± SD; Pack-years *p > 0.05; **p > 0.05; ***p > 0.05
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to be better than FEV1 at predicting the risk of 
death from respiratory and other causes, among 
COPD patients [10]. The other multidimensional 
indices are the ADO index (Age, Dyspnoea, FEV1) 
and DOSE index (Dyspnea, FEV1, Smoking status 
and Exacerbations) [11, 12].
The new GOLD consensus report update (as 
of 30 December, 2011) uses airflow limitation, 
history of COPD exacerbations, and symptoms to 
classify and grade the severity of the disease [9]. 
Based on this new approach to COPD, described 
as combined personalised assessment of COPD, 
our patients were stratified into categories ABCD. 
It refers to both men and women. Patients with 
severe and very severe COPD on the basis of 
FEV1, amounting to 168 (53,3%) in total, were 
stratified to category D, but 24 (7.62%) of them 
with accompanying severe decline in FEV1 ap-
peared to have resistance to exacerbations and 
they were included in category C. Twenty-one 
(12.5%) patients with moderate decline in FEV1 
but with more symptoms of COPD were also stra-
tified into category D instead category B because 
they experienced a lot of exacerbations of COPD. 
Thus, classification to category D in this group 
of patients was determined by the frequency 
of exacerbations and admission to hospital [9]. 
Analysis of the data from the COPD gene large 
patient cohort study also showed a small number 
of patients in category C (7.9%) and the largest 
group of patients were stratified to category D 
(38%) [23]. Thus, we assume that patients with 
a low value of FEV1 and low level of symptoms of 
COPD but with frequent exacerbation symptoms 
make up a small group of COPD patients. On the 
grounds of the study carried out by Hurst et al. [24], 
the frequency and severity of exacerbations which 
characterised the patients with ‘frequent’ and 
‘infrequent’ exacerbations tended to remain in the 
same category. There are two proposed methods 
for assessing exacerbation risk. The first method 
is based on a patient’s medical history of exacer-
bations. According to the 2011 GOLD report, two 
or more episodes of COPD exacerbations per year 
classifies him/her as a ‘frequent exacerbator’ [9]. 
From the definition these patients should be 
stratified to category C or D. But clinical study 
results show that exacerbations evoke more cli-
nical symptoms of COPD, which are presented in 
higher CAT and mMRC scores [25]. Moreover, exa-
cerbations have a significant negative influence 
on the clinical course of COPD [26, 27], which is 
why the patients with mild or moderate values of 
FEV1 should be stratified into category D instead 
of category C. In our study used this method since 
we were in possession of all the data from the 
patients’ medical histories. The second method 
relies on FEV1. When this parameter is below 50% 
of the predicted value, which is characterised by 
a great number of exacerbations and a few symp-
toms, the patient is stratified into category C. The 
number of exacerbations can be calculated from 
the 2011 GOLD report [9] based on the ECLIPSE, 
TORCH, and UPLIFT studies [6–8]. However, 
a history of previous exacerbations is the best 
predictor of future exacerbation risk in all stages 
of COPD severity [24]. The COPD exacerbations 
imply a worse prognosis [26–28].
While analysing the frequency of COPD exa-
cerbations we should keep in mind that patients 
often do not report exacerbations to health care 
professionals [27]. Exacerbations of COPD and, 
especially, any hospital admissions are asso-
ciated with a poor prognosis [28, 29]. It is well 
documented that COPD exacerbations are serious 
events because they usually have an infectious 
origin and are associated with inflammation of the 
respiratory system and with systemic inflamma-
tion [30]. Thus, J. Wędzicha [31] postulates that 
patients with frequent exacerbations but mild or 
moderate symptoms should fall into one category 
regardless of FEV1 decline. She also concludes 
that a simpler version of categorisation is neces-
sary. Categories A and B should include patients 
with mild and moderate symptoms represented 
by CAT scores, and then a broader higher-risk 
exacerbation group should be combined with 
frequent exacerbators, especially patients with 
hospital admissions [31]. Han et al. [23], while 
analysing a COPD gene cohort and considering 
the 2011 GOLD report, stated that where exa-
cerbation risk, as defined by FEV1 or previous 
exacerbation history, is not identical, further 
classification to category C or D should be used. 
In their stratification patients in C1 and D1 catego-
ries met FEV1 criteria, C2 and D2 met exacerbation 
criteria only, and C3 and D3 met both FEV1 and 
exacerbation criteria. This stratification of COPD 
patients is reasonable but complicated in clinical 
practice. That is why in our study we only used 
the simpler stratification into category C and D, 
but we suggest that a simpler version with one 
group of patients with frequent exacerbation is 
better. The 2013 GOLD report propagates that 
for classification of patients, the clinical COPD 
questionnaire (CCQ) is a reliable, short and easy, 
self-administered, validated questionnaire. 0-1 
points in the CCQ is considered for patients from 
categories A and C, and ≥ 1 point is for patients 
from categories B and D [32].
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The mean time of duration of COPD was 6.3 
years. Short duration of COPD results only from 
late diagnosis of the disease, which took place in 
a specialist clinic but not in primary care. Even 
in patients with severe decline in FEV1 (≤ 50% of 
the predicted value), their COPD was diagnosed 
in a short time. It must be stressed that COPD is 
a disease that takes a long time to diagnose when 
the inflammatory process is already responsible 
for big changes in the respiratory system as well 
as in extrapulmonary organs [30]. COPD is an 
under-diagnosed disease because it is usually not 
detected until patients seek medical attention for 
dyspnoea or an exacerbation.
Multiple COPD characteristics are termed 
COPD phenotypes. They classify patients into 
distinct subgroups that provide prognostic in-
formation and allow improvement of current 
clinical practice. Han et al. [33] characterised a 
phenotype of COPD as a single attribute or com-
bination of disease attributes that describe the 
differences between patients with COPD. These 
attributes refer to symptoms, exacerbations, re-
sponse to therapy, rate of disease progression, or 
death [24, 33, 34]. Other phenotypes have been 
proposed, for example a fast decliner with a gre-
ater than average fall in FEV1, and inflammatory 
phenotype with elevated serum concentration of 
inflammatory markers [35, 36]. A different phe-
notype is presented by current smokers, but this 
phenotype is in all other phenotypes. The special 
phenotype is the overlap COPD — asthma. This 
mixed phenotype is diagnosed in 13% of COPD 
patients with a history of asthma before the age 
of 40 years [37].
Tobacco smoking is the main risk factor of 
COPD and it is also the main determinant of poor 
outcome in subjects who suffer from COPD [38, 39]. 
De Marco et al. [39] showed that COPD may start 
early in life and that smoking is the main risk 
factor for COPD. The other strong risk factors 
are airway hyperresponsiveness, respiratory 
infections in childhood, and a family history of 
asthma. It is believed that COPD occurs after 20 
to 25 pack-years of exposure. De Marco et al. [40] 
showed that in their cohort about half of the in-
cident cases of COPD had smoked for less than 20 
pack-years. Thus, there is a hypothesis that COPD 
does not reflect only the cumulative exposure 
to cigarette smoke, but also early interaction of 
tobacco smoking with some genetic or immuno-
logical host characteristics [41]. 
In the studied group, the average time of 
smoking was 47.1 years. But in all categories, 
female groups were lower (but not significantly) 
than male groups (Table 3). We cannot establish 
whether 20 pack-years is enough for developing 
advanced stadium of COPD as we diagnosed our 
patients already in this stadium. Over 45% of the 
patients we studied were current smokers, but 
they were more prevalent in high-risk group D 
(51.7%). This data is contrary to the results pre-
sented by Han et al. [23], who found that current 
smoking was less prevalent in this category of 
patients: 50% in category A vs. 10% and 28% in 
categories C3 and D3, respectively. We assume 
that current smoking among patients in group 
D is responsible for frequent exacerbations and 
decline in FEV1. These differences in our and 
Han’s outcomes in reference to current smoking 
probably result from cultural habits and poorer 
levels of education of our patients. 
In summary, we have demonstrated that the 
COPD population is heterogeneous with regard 
to the symptoms, value of FEV1, and susceptibi-
lity to exacerbations. Over half of the patients 
were in category D, which is characterised by 
frequent exacerbations, and over 51% of them 
were current smokers. The identification of this 
group of patients is very important from a clinical 
point of view because COPD exacerbations can be 
prevented by numerous methods, thus reducing 
acute events. First, intensive smoking cessation 
strategies must be adopted in these patients. Mo-
reover, influenza and pneumococcal vaccination 
should be offered to all COPD patients together 
with treatment with long-acting inhaled bron-
chodilators and\or long acting anticholinergic 
agents, with or without inhaled corticosteroids 
and a phosphodiesterase inhibitor. Triple inhaled 
therapy is also recommended [9].
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